BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
77.25
+3.43 (4.65%)
At close: Jan 9, 2026, 4:00 PM EST
76.00
-1.25 (-1.62%)
After-hours: Jan 9, 2026, 7:36 PM EST
BridgeBio Pharma Market Cap
BridgeBio Pharma has a market cap or net worth of $14.89 billion as of January 9, 2026. Its market cap has increased by 183.65% in one year.
Market Cap
14.89B
Enterprise Value
16.10B
1-Year Change
183.65%
Ranking
Category
Stock Price
$77.25
Market Cap Chart
Since June 27, 2019, BridgeBio Pharma's market cap has increased from $3.32B to $14.89B, an increase of 348.43%. That is a compound annual growth rate of 25.78%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 9, 2026 | 14.89B | 0.99% |
| Dec 31, 2025 | 14.74B | 184.24% |
| Dec 31, 2024 | 5.19B | -26.16% |
| Dec 29, 2023 | 7.02B | 516.56% |
| Dec 30, 2022 | 1.14B | -53.61% |
| Dec 31, 2021 | 2.46B | -71.83% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 27, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 952.29B |
| Johnson & Johnson | 492.44B |
| AbbVie | 388.97B |
| UnitedHealth Group | 311.59B |
| AstraZeneca | 295.57B |
| Merck & Co. | 274.34B |
| Novartis AG | 272.98B |
| Novo Nordisk | 263.81B |